All In Biotech

Drug Trial Radar · NCT01661621

Antimuscarinics as the First-line Treatment for Male With IPSS-V/S≤1

Antimuscarinics as the First-line Treatment for Male With International Prostate Symptom Score (IPSS) Voiding-to-storage Subscore Rati (IPSS-V/S)≤1-- A Prospective Randomized Study Comparing With α-blockers

Last checked: Nov 19, 2026Latest source record: Jun 25, 2014 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingRandomized with 395 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

395

Actual

Start

Aug 2012

Primary completion

Aug 2013

Study completion Aug 2013

Sponsor

Lead sponsor
Buddhist Tzu Chi General HospitalAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Aug 9, 2012

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
Who can join
Male only, from 40 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This study is a prospective randomized, open label, controlled, double arm, post-marketing study to compare the treatment efficacy of first-line antimuscarinics and α-blockers monotherapy for men with moderate to severe lower urinary tract symptoms (LUTS) (International Prostate Symptom Score (IPSS-T) ≥8) and IPSS voiding-to-storage subscore ratio (IPSS-V/S) ≤1.

Conditions

  • Bladder Outlet Obstruction

Interventions

  • Detrusitol 4 mg QDDrug

    Group 1

  • Doxazosin 4 mg QDDrug

    Group 2

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The Global Response Assessment (GRA) After the Treatment DayTime frame: 1 month after initial treatment

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Buddhist Tzu Chi General Hospital

    Hualien City, Taiwan

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.